Literature DB >> 19958782

Cathepsin L, target in cancer treatment?

Jacqueline M Lankelma1, Daniëlle M Voorend, Temo Barwari, Joris Koetsveld, Anne H Van der Spek, Alexander P N A De Porto, Geeske Van Rooijen, Cornelis J F Van Noorden.   

Abstract

Cathepsin L, a cysteine protease, is considered to be a potential therapeutic target in cancer treatment. Proteases are involved in the development and progression of cancer. Inhibition of activity of specific proteases may slow down cancer progression. In this review, we evaluate recent studies on the inhibition of cathepsin L in cancer. The effects of cathepsin L inhibition as a monotherapy on apoptosis and angiogenesis in cancer are ambiguous. Cathepsin L inhibition seems to reduce invasion and metastasis, but there is concern that selective cathepsin L inhibition induces compensatory activity by other cathepsins. The combination of cathepsin L inhibition with conventional chemotherapy seems to be more promising and has yielded more consistent results. Future research should be focused on the mechanisms and effects of this combination therapy. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19958782     DOI: 10.1016/j.lfs.2009.11.016

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  55 in total

Review 1.  Cathepsin L targeting in cancer treatment.

Authors:  Dhivya R Sudhan; Dietmar W Siemann
Journal:  Pharmacol Ther       Date:  2015-08-20       Impact factor: 12.310

2.  Inhibition of cathepsin L sensitizes human glioma cells to ionizing radiation in vitro through NF-κB signaling pathway.

Authors:  Neng Yang; Pan Wang; Wen-juan Wang; Yun-zhen Song; Zhong-qin Liang
Journal:  Acta Pharmacol Sin       Date:  2015-02-09       Impact factor: 6.150

3.  A new pathway that regulates 53BP1 stability implicates cathepsin L and vitamin D in DNA repair.

Authors:  Ignacio Gonzalez-Suarez; Abena B Redwood; David A Grotsky; Martin A Neumann; Emily H-Y Cheng; Colin L Stewart; Adriana Dusso; Susana Gonzalo
Journal:  EMBO J       Date:  2011-07-12       Impact factor: 11.598

4.  Significance of heparanase in cancer and inflammation.

Authors:  Israel Vlodavsky; Phillip Beckhove; Immanuel Lerner; Claudio Pisano; Amichai Meirovitz; Neta Ilan; Michael Elkin
Journal:  Cancer Microenviron       Date:  2011-08-03

5.  Affinity-Enhanced Luminescent Re(I)- and Ru(II)-Based Inhibitors of the Cysteine Protease Cathepsin L.

Authors:  Matthew Huisman; Jacob P Kodanko; Karan Arora; Mackenzie Herroon; Marim Alnaed; John Endicott; Izabela Podgorski; Jeremy J Kodanko
Journal:  Inorg Chem       Date:  2018-06-08       Impact factor: 5.165

Review 6.  Cysteine cathepsins: their role in tumor progression and recent trends in the development of imaging probes.

Authors:  Reik Löser; Jens Pietzsch
Journal:  Front Chem       Date:  2015-06-23       Impact factor: 5.221

7.  Optimization of dipeptidic inhibitors of cathepsin L for improved Toxoplasma gondii selectivity and CNS permeability.

Authors:  Jeffery D Zwicker; Nicolas A Diaz; Alfredo J Guerra; Paul D Kirchhoff; Bo Wen; Duxin Sun; Vern B Carruthers; Scott D Larsen
Journal:  Bioorg Med Chem Lett       Date:  2018-03-09       Impact factor: 2.823

8.  Enhanced tumor retention of NTSR1-targeted agents by employing a hydrophilic cysteine cathepsin inhibitor.

Authors:  Wei Fan; Wenting Zhang; Sameer Alshehri; Trey R Neeley; Jered C Garrison
Journal:  Eur J Med Chem       Date:  2019-05-25       Impact factor: 6.514

9.  Cathepsin L inactivation leads to multimodal inhibition of prostate cancer cell dissemination in a preclinical bone metastasis model.

Authors:  Dhivya R Sudhan; Christine Pampo; Lori Rice; Dietmar W Siemann
Journal:  Int J Cancer       Date:  2016-02-05       Impact factor: 7.396

10.  Lysosomal instability and cathepsin B release during acetaminophen hepatotoxicity.

Authors:  Benjamin L Woolbright; Anup Ramachandran; Mitchell R McGill; Hui-min Yan; Mary Lynn Bajt; Matthew R Sharpe; John J Lemasters; Hartmut Jaeschke
Journal:  Basic Clin Pharmacol Toxicol       Date:  2012-09-25       Impact factor: 4.080

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.